Cilostazol is a phosphodiesterase-3 inhibitor that both inhibits platelet aggregation and dilates peripheral arteries, whereas aspirin primarily works by irreversibly inhibiting platelet cyclooxygenase. Cilostazol therefore improves walking distance in intermittent claudication, a benefit not provided by aspirin alone.
Most statins (e.g., atorvastatin, simvastatin) do not have a known interaction with cilostazol. However, any co-prescribed drug should be reviewed by your physician or pharmacist to confirm safety.
Cilostazol can be used in patients with mild to moderate renal impairment, but dosage adjustments may be necessary for severe kidney disease. Your healthcare provider will assess kidney function before prescribing.
Patients often report measurable improvement after 2 to 4 weeks of consistent therapy, with maximal benefit observed around 8 weeks.
Cilostazol primarily acts on peripheral vessels and has minimal effect on systemic blood pressure. However, individual responses can vary, and any significant changes should be reported to your clinician.
Yes, but carry the medication in its original labeled container, bring a copy of the prescription, and be aware of any import restrictions for prescription drugs in the destination country.
Cilostazol is itself a generic medication; various manufacturers may market it under different brand names, but the active ingredient remains the same.
A mild headache is common and often resolves on its own. If the headache is severe, persistent, or accompanied by visual changes, seek medical evaluation promptly, as it could signal a rare adverse reaction.
Ginkgo biloba has mild antiplatelet activity and could theoretically increase bleeding risk when combined with cilostazol. Discuss all herbal and supplement use with your healthcare provider.
Cilostazol can increase heart rate and myocardial oxygen demand, potentially worsening symptoms in patients with advanced heart failure (NYHA Class III-IV). This contraindication is based on clinical safety data.
Cilostazol is a quinolinone derivative classified as a phosphodiesterase III inhibitor. This active compound functions primarily as a vasodilator and antiplatelet agent. By altering the chemical signaling within blood cells and vessel walls, it helps improve blood flow throughout the body.
This substance is the core active ingredient in various formulations, most notably marketed under brand names such as Pletal. It is designed to assist individuals experiencing specific circulatory challenges by reducing the stickiness of blood components and helping vessels remain widened.
In the Hong Kong healthcare market, this compound is typically dispensed as an oral, immediate-release tablet. While branded versions exist, pharmacies also provide generic equivalents that share the same chemical structure and potency requirements. Tablets are designed to transition through the digestive system and release the API into the bloodstream, where it takes effect over several hours.
Health professionals may utilize this substance to manage symptoms associated with chronic circulatory conditions. The primary applications include:
This compound works by blocking a specific enzyme known as phosphodiesterase III. By inhibiting this enzyme, the substance increases the levels of a chemical messenger called cyclic AMP (cAMP) within platelets and blood vessels. Increased cAMP levels prevent platelets from clumping together, which helps reduce the risk of clot formation. Simultaneously, this process relaxes the smooth muscles lining the blood vessels, allowing arteries to expand. This widening effect decreases resistance, permitting more efficient oxygenated blood delivery to the limbs.
Many individuals notice mild headaches, particularly during the initial stage of therapy. Others may experience loose stools, dizziness, or a temporary sensation of a racing or pounding heartbeat.
Some people may experience signs of internal bleeding, such as unusual bruising or persistent nosebleeds. If an individual develops signs of an irregular heart rhythm or experiences allergic reactions like swelling of the face or difficulty breathing, immediate clinical assessment is necessary.
This substance is generally avoided by individuals with a history of heart failure, as it may exacerbate cardiac workload. It is also not suitable for those with active bleeding disorders or severe, uncontrolled hypertension.
Combining this compound with other blood-thinning agents or antiplatelet drugs can heighten the risk of bleeding. Certain enzyme-inhibiting drugs-commonly used for fungal infections or gastric acid control-may alter how the body clears this substance. Always refer to your specific medication’s clinical insert for a complete assessment of known interactions.
Cilostazol is usually taken on an empty stomach to ensure consistent absorption. Clinical effectiveness is often evaluated over several weeks, as the improvements in circulation occur gradually. Long-term adherence is frequently required to maintain the benefits for vascular health. For detailed usage, dosing, and administration, refer to the specific medication's clinical information.
This information serves as an educational resource regarding the properties and applications of Cilostazol and should not be interpreted as professional medical advice. Medications under this classification, such as Pletal, vary in formulation and requirement; clinical outcomes depend on individual history and dosage accuracy. We disclaim any liability for clinical applications or decisions made based on this text. For specific treatment, dosing, or safety concerns, consult the provided medication labeling and your healthcare professional.
